1-6 of 6
Karen E. Parrish
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Available to Purchase
Sani H. Kizilbash, Shiv K. Gupta, Karen E. Parrish, Janice K. Laramy, Minjee Kim, Gautham Gampa, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 1009–1018.
https://doi.org/10.1158/1535-7163.MCT-20-0640
Published: 01 June 2021
View articletitled, In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Open the PDF for In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling in another window
Includes: Supplementary data
Journal Articles

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Free
Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A Decker, Jeanette E. Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F. Parney, Panos Z. Anastasiadis, Nathalie Y.R. Agar, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (9): 1893–1901.
https://doi.org/10.1158/1535-7163.MCT-17-0600
Published: 04 September 2018
View articletitled, Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Open the PDF for Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier in another window
Includes: Supplementary data
Journal Articles

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Free
Sani H. Kizilbash, Shiv K. Gupta, Kenneth Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2735–2746.
https://doi.org/10.1158/1535-7163.MCT-17-0365
Published: 03 December 2017
View articletitled, Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Open the PDF for Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model

Free
Rajendar K. Mittapalli, Alexander H. Chung, Karen E. Parrish, Donna Crabtree, Kyle G. Halvorson, Guo Hu, William F. Elmquist, Oren J. Becher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 819–829.
https://doi.org/10.1158/1535-7163.MCT-15-0093
Published: 05 May 2016
View articletitled, ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model
Open the PDF for ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model in another window
Includes: Supplementary data
Journal Articles

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Free
Karen E. Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2735–2743.
https://doi.org/10.1158/1535-7163.MCT-15-0553
Published: 06 December 2015
View articletitled, Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Open the PDF for Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System in another window
Includes: Supplementary data
Journal Articles

Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.

Free
Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, Katrina Bakken, Jann N. Sarkaria, William F. Elmquist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C81.
https://doi.org/10.1158/1535-7163.TARG-13-C81
Published: 01 November 2013
View articletitled, Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.